A-Alpha Bio: Funding, Investors & Team (Oct 2026)
A-Alpha Bio is a company that offers cell-based tools to efficiently measure protein interactions, facilitate target discovery, library screening, and preclinical drug testing. Their groundbreaking product, AlphaSeq, is a cell-based platform technology that will revolutionize the measurement of protein interactions. A-Alpha Bio consists of a team of professionals specializing in synthetic biology, structural biology, and next-generation sequencing, collaborating to eliminate the obstacle faced by the industry.
A-Alpha Bio has raised $59.3M across 4 funding rounds on record, the most recent an undisclosed round of $14.5M announced in May 2024.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
A-Alpha Bio Company Profile and Key Stats
Latest funding round on record: May 2024.
A-Alpha Bio Funding Rounds
A-Alpha Bio raised $20.0M in a Series A announced in Sep 2021.
1.7 years later, an undisclosed round of $2.4M was announced in May 2023.
2 months later, a Series A of $22.4M was announced in Jul 2023.
10 months later, an undisclosed round of $14.5M was announced in May 2024.
A-Alpha Bio Founders and Leadership Team
Contact details for the A-Alpha Bio team: 2 of 2 have an email address on file.
Start 14-day free trial →A-Alpha Bio Funding Compared to Other Biotechnology Startups
A-Alpha Bio's latest round of $14.5M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like A-Alpha Bio in Biotechnology and Seattle
Companies Similar to A-Alpha Bio
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
Datavant is a developer of a healthcare data platform dedicated to assisting in protecting, matching, and…
A-Alpha Bio Funding FAQs
What does A-Alpha Bio do?
A-Alpha Bio is a company that offers cell-based tools to efficiently measure protein interactions, facilitate target discovery, library screening, and preclinical drug testing. Their groundbreaking product, AlphaSeq, is a cell-based platform technology that will revolutionize the measurement of protein interactions. A-Alpha Bio consists of a team of professionals specializing in synthetic biology, structural biology, and next-generation sequencing, collaborating to eliminate the obstacle faced by the industry.
How much funding has A-Alpha Bio raised?
A-Alpha Bio has raised $59.3M across 4 rounds on record. The most recent is an undisclosed round of $14.5M announced in May 2024.
When did A-Alpha Bio last raise funding?
A-Alpha Bio's most recent funding round on record is an undisclosed round of $14.5M, announced in May 2024.
Who founded A-Alpha Bio?
FundedIQ lists David Younger (Founder), Randolph Lopez (Founder) at A-Alpha Bio.
Where is A-Alpha Bio headquartered?
A-Alpha Bio is based in Seattle, Washington, United States.
How many employees does A-Alpha Bio have?
A-Alpha Bio is in the 11-50 employee band.
How does A-Alpha Bio's funding compare to other Biotechnology startups?
A-Alpha Bio's latest round of $14.5M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's A-Alpha Bio Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for A-Alpha Bio is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.